Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative ...

The FDA expanded the indications for guselkumab (Tremfya) to include adults with moderately to severely active ulcerative colitis, Johnson & Johnson announced on Wednesday. Approval of the dual-acting ...

A combination of the herbal extracts curcumin and Qing Dai can induce remission in a significant proportion of patients with active ulcerative colitis (UC), according to the results of a phase 2 ...

The submission is supported by data from the True North trial that assessed ozanimod as an induction and maintenance therapy for adults with moderately to severely active UC who had an inadequate ...

Significantly more patients with moderately to severely active ulcerative colitis achieved clinical remission with the investigational monoclonal antibody tulisokibart compared with placebo, a ...

Patients with active ulcerative colitis may be able to reduce symptoms and achieve remission by taking a plant-based treatment combining the herbal compounds curcumin and qingdai, preliminary results ...

The approval was based on data from two phase 3 induction studies and one phase 3 maintenance study. The Food and Drug Administration (FDA) has approved Rinvoq ® (upadacitinib) for the treatment of ...